Development of new medical interventions takes too long, costs too much and too often ends in failure. One significant hurdle remains - the low predictive value of preclinical models, which are associated with high attrition rates owing to a lack of clinical efficacy and/or excessive toxicity. Cellular systems are part of the toolbox for prediction of efficacy, toxicity and drug response, with the added benefit of helping to reduce the use of animals in research.
This session will look into the latest development and future perspectives of cellular models that better resemble the tissue architecture and complexity of human systems. For instance, in oncology, drug screening models involving three-dimensional, multi-cellular cultured (3D) spheroids use culture methods that mimic the in vivo environmental conditions such as hypoxia, while screening with patient-derived primary cells or patient-derived organoids enables precision medicine approaches. In the toxicology field, attention has turned towards the promise of the human-on-a-chip model. By providing an overview of the various models available and their limitations, the session will help apprise drug developers of the latest advancements in the field.
Session ID: 21856